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Abstract
Background: Hilar cholangiocarcinoma is a rare but highly lethal type of cancer. A minority of patients
present with resectable disease. Surgery remains the only treatment modality offering a chance of
long-term survival. Unresectable patients are typically offered palliative treatment. The aim of this sys-
tematic review was to summarize the evidence for neoadjuvant therapy followed by surgical resection in
patients presenting with hilar cholangiocarcinoma.
Methods: Cochrane databases, Medline, PubMed and EMBASE were systematically searched to iden-
tify articles describing neoadjuvant therapy and surgical resection or re-assessment of resectability in
patients with hilar cholangiocarcinoma. Included were all articles with original research. Study selection
and data extraction were performed separately by two reviewers using a standardized protocol.
Results: From 732 articles 8 full text articles and 2 abstracts met the inclusion criteria. The 2 abstracts
and 1 full text article were case reports, 3 articles were retrospective and 4 were prospective studies
(2 phase I and 2 phase II studies). Photodynamic therapy, chemotherapy and radiation therapy were used
in various indications in populations that included patients with hilar cholangiocarcinoma, some of which
were primarily unresectable. Overall quality of articles was limited.
Conclusion: Current evidence suggests that neoadjuvant therapy in patients with unresectable hilar
cholangiocarcinoma can be performed safely and in a selected group of patients can lead to subsequent
surgical R0 resection. Surgical resection of downstaged patients should be assessed in properly designed
phase II studies.
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Background
Cholangiocarcinomas account for approximately 3% of all gas-
trointestinal malignancies,1,2 this represents 5000 new patients in
the US annually.2,3 From an anatomical point of view approxi-
mately 60–70% are located within 2 cm from the bifurcation of
the common bile duct (hilar cholangiocarcinoma, also called
Klatskin tumour), extrahepatic cholangiocarcinomas occur in
approximately 20–30% of patients and intrahepatic in 5–10%.2,4
Surgery represents the only chance of long-term survival and cure
and the 5-year survival after an R0 resection of hilar cholangiocar-
cinoma is in the range of 30–50%.2,5–11
Unfortunately, the majority of patients who present with hilar
cholangiocarcinoma are not resectable owing to the local extent
(involvement of vessels or bilateral extension beyond the second-
ary radicals) or because of the presence of metastatic disease.2,12,13
This was described in a retrospective review by Jarnagin et al.,8
when 65% of the 225 patients with hilar cholangiocarcinoma
treated at MSKCC between 1991 and 2001 had unresectable
disease, 32% as a result of metastases and 23% because of locally
unresectable disease. Patients with unresectable disease are usually
referred only for palliative therapy. It may prolong their life as well
as control their symptoms with the use of chemotherapy, radia-
tion or photodynamic therapy (PDT).14–20 The expected survival
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in this patient population is 6–12 months depending on the
therapy used.16
The outcomes of incomplete R1/R2 resection in spite of the use
of adjuvant therapy are comparable with palliative PDT without
resection.21 This makes decision making in marginally resectable
patients challenging. The benefit of an aggressive approach if a R0
resection is achieved needs to be weighed against the impact on
quality of life without a survival benefit in patients with a R1/R2
resection.
There is no general consensus when it comes to use of neoad-
juvant and adjuvant therapy. Multiple guidelines, reviews and
opinions describe that these therapies are currently not indicated.
They suggest further research as there is lack of sufficient evidence
from prospective studies. The only exception is the use of neoad-
juvant chemoradiation prior to the liver transplant in a highly
selected group of patients with hilar cholangiocarcinomas. It has
been extensively studied and neoadjuvant therapy in this setting is
currently a requirement.22–27
The authors hypothesize that a certain number of patients with
locally advanced hilar cholangiocarcinoma, currently only offered
palliative therapy, could be rendered resectable with the use of
neoadjuvant therapy. Downstaging and subsequent resection
could potentially improve their outcome. Similarly, marginally
resectable patients might benefit from downstaging of their
tumours by increasing their chance for an R0 resection.
The aim of this review is not to compare regimens or to identify
the one with the best pathological response. This has been done in
the past in great detail16 and with new emerging chemotherapeutics
it will continue to evolve. The aim is to describe clinical relevance of
neoadjuvant therapy. Only complete pathological response guar-
antees clinical significance in terms of subsequent resectability.
Methods
This study was conducted in accordance with the standards of
quality for reporting systematic reviews (PRISMA).28 A formal
protocol has not been created on the web for access. The authors
did not receive any funding for the systematic review.
The authors sought to answer a question: What is the evidence
with regards to the safety and efficacy of downstaging locally
advanced hilar cholangiocarcinoma with the use of neoadjuvant
therapy and subsequently resecting them?
Search strategy
Using the Cochrane databases, Medline, PubMed and EMBASE a
search was performed in October 2012 using either keyword or
subject heading (MeSH) ‘cholangiocarcinoma’ OR ‘Klatskin
tumor’ AND keyword ‘neoadjuvant’ or subject heading ‘neoadju-
vant therapy’. Searches were auto exploded and no limits were
used. In terms of identification of additional papers during full
text reviews, six additional papers were identified and all were
added to the full text reviews. The authors kept the initial search
terms broad in order to identify all potentially relevant articles.
Study selection
It was very likely that multiple different types of cholangiocarci-
nomas or even other types of biliary tract cancers were grouped
together in some studies. The focus on exclusion of articles that
did not contain any patients with specifically hilar cholangiocar-
cinoma was left for the second stage of the review process. The aim
was to include all articles that described at least a subset of patients
with hilar cholangiocarcinoma.
Similarly, in spite of a very specific research question in terms of
the indication for neoadjuvant therapy, all articles describing
safety and efficacy of neoadjuvant therapy followed by resection
were included. This would include articles describing the use of
neoadjuvant therapy in resectable patients with the aim of
improving local control or survival. The rationale for that was a
reasonable expectation that resection after neoadjuvant therapy
will have a similar morbidity and mortality profile regardless of
indication.
As a result, all articles that contained original research regarding
any neoadjuvant therapy used for patients with resectable or unre-
sectable hilar cholangiocarcinoma who subsequently underwent
either an assessment of resectability or a resection were included.
(Fig. 1)
Excluded were all review and expert opinion articles without
original data, chemotherapy, radiation or photodynamic therapy
in an adjuvant or palliative setting as well as papers describing
neoadjuvant therapy followed by an orthotopic liver transplant.
Also studies describing only response rates without an assessment
of subsequent resectability were excluded because resectability
cannot be assumed purely based on overall decreased volume of
the tumour.
Two authors (J.G. and P.G.) independently screened titles and
abstracts of all studies for inclusion eligibility. Any disagreements
were settled by including all of the identified papers in full-text
review.
All articles were written either in English or German language,
translation from German was performed by the same two authors.
Data extraction
The same two authors then extracted data from included articles;
this was again done through independent work. The developed
protocol included description of the study method, the number of
patients, the reason for unresectability, the type of neoadjuvant
regimen, the type of subsequent reassessment of resectability,
timing and type of subsequent surgery, outcome after surgery
including complications and survival, and the type of conclusion
the study suggested.
Results
Trial flow
The search and the whole screening process are described in the
flow chart (Fig. 1). Agreement on selected studies was 100%.
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Data extraction
Table 1 shows original data extracted from the articles.
Case reports
The authors identified three case reports;29–31 two of them30,31 were
added to the overview only based on abstracts as full text articles
were not available for review. These two abstracts describe two
patients with unresectable hilar cholangiocarcinoma who success-
fully underwent a surgical resection after being downstaged with
neoadjuvant therapy. Tada et al.30 performed an extended left
hepatectomy with partial resection of the portal vein, Sato et al.31
describe an extended left hepatectomy with a caudate lobectomy
with resection and reconstruction of the hepatic artery. In both
cases all margins were negative. With all limitations, these case
reports show at least a potential for aggressively treating a selected
group of patients who would only be offered palliative treatment
based on current recommendations.
The third case report29 describes neoadjuvant photodynamic
therapy used in a resectable patient with hilar cholangiocarcinoma
who underwent a resection of extrahepatic bile duct together with
a Whipple’s procedure on the 23rd day after PDT. Histological
examination revealed a complete response to the depth of 4 mm
and this paper suggests that PDT is feasible as a neoadjuvant
therapy. It is important to stress the fact that this case suggests the
use of neoadjuvant PDT in resectable patients. The indication for
that is not clearly stated in the study. We can speculate that it was
likely to improve local control as opposed to downstaging which
would be difficult to achieve with the result PTD offers.
Retrospective studies
Retrospective review papers32–34 used hospital databases to
describe and compare neoadjuvant and adjuvant therapy.
The first one, by Nelson et al.,33 identified a cohort of 12
patients out of 45 with both proximal and distal extrahepatic
cholangiocarcinomas who underwent neoadjuvant therapy. 10
were initially unresectable and 2 were resectable but treated with
external beam radiation therapy and fluoropyrimidine-based
chemotherapy as sensitizer because of physician preference. The
other 33 patients underwent resection followed by adjuvant
therapy. As a result, 11 out of the 12 patients in neoadjuvant group
underwent an R0 resection, 3 with complete pathological
response. There was similar surgical morbidity and 5-year survival
of 53% in the neoadjuvant group versus 23% in the adjuvant
group which was statistically non-significant.
The second study by Glazer et al.32 grouped all 157 resectable
patients with gallbladder cancer and cholangiocarcinoma and
compared neoadjuvant, adjuvant chemotherapy and adjuvant
chemoradiation cohorts in their outcomes. The study suggested
that neoadjuvant therapy in 28 patients delayed surgery on
average by 6.8 months and with that resulted in a median survival
of 42.3 versus the 53.5 months for the upfront resected cohort,
which was statistically significant. Unfortunately, no patient char-
acteristics or selection criteria and indications were described,
besides the fact that a panel of experts decided which patient was
going to be treated using which strategy. It is reasonable to there-
fore hypothesize that patient selection bias is a major factor influ-
encing outcome. The neoadjuvant group then possibly included
patients with AN overall worse prognosis.
The third study by Gerhards et al.34 describes the use of neoad-
juvant external beam radiation therapy using 3 ¥ 3.5 Gy as a
means of decreasing the risk of implantation metastases after
ERCP or PTC drainage procedures. With this strategy none of the
19 patients with preoperative drainage procedures and neoadju-
vant EBRT developed implantation metastases versus 20 % in case
Total number of potential articles
identified n = 732 Additional articles identified n = 6
Articles screened n = 738
Full-texts not available
(abstracts included) n = 2
Excluded after abstract review n = 429
Duplicates n = 187
Full-texts reviewed
n = 120
Articles excluded n = 112
 Review n = 67
 Neoadjuvant followed by transplant n = 17
 Only intrahepatic/distal CC n = 3
 Neoadjuvant tx not a separate variable n = 3
 Chemo/rad tx not followed by resection n = 20
 Experimental studies n = 2
Studies included
n = 8
Figure 1 Flow chart of steps in systematic review
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of preoperative drainage and no neoadjuvant therapy described in
a previous study.35
Prospective studies
Only four prospective studies that fulfilled the inclusion criteria
were conducted. Two were phase I studies36,37 and two were phase
II studies.21,38
McMasters et al.36 in the original article ‘Neoadjuvant Chemo-
radiation for Extrahepatic Cholangiocarcinoma’ in 1997 sug-
gested the idea of pre-operative neoadjuvant chemoradiation with
the intention to downstage hilar and distal cholangiocarcinomas
and improve R0 resectability. In their non-randomized study they
treated a total of nine patients, six of which were deemed unre-
sectable, with a combination of 5-FU chemotherapy and radiation
therapy without a standardized protocol (neoadjuvant external
beam radiation therapy in doses ranging from 30 to 50.4 Gy,
post-operative 10 Gy brachytherapy and three distal cholangiocar-
cinomas received 10 Gy intra-operative external beam radiation
boost). As a result, all nine patients underwent an R0 resection,
compared with 45% (14/31) in a group that did not receive any
neoadjuvant therapy. A complete response occurred in three
patients. There were no major complications in the neoadjuvant
group (three minor wound complications and one cardiac
arrhythmia). As a result, this study suggested that neoadjuvant
chemoradiation therapy can be done safely, improves the ability to
perform a resection with tumour-free margins and provides a
significant antitumour response.
The limitations of this study are related to different doses and
timing of neoadjuvant therapy for each patient as well as unclear
selection of patients with hilar and distal cholangiocarcinoma,
both resectable and unresectable. Nevertheless, this study does
describe patients with initially unresectable hilar cholangiocarci-
noma who were able to safely undergo an R0 resection.
The second phase I study is a Japanese NACRAC study by
Katayose et al.,37 which suggested that the recommended dose of
Table 1 Characteristics of included articles and summary of outcomes
Study Type of study Type of
neoadjuvant
Tx
Indication N neo Resectability Anatomy Results Conclusion
1 McMasters
et al., 199736
non-randomized
prospective
study
5-FU and
EBRT
Downstaging 9 6 unresectable 5 hilar,
4 distal CC
100% R0
resection
neoadjuvant therapy
is safe and
improves
resectability
2 Berr et al.,
200029
case report PDT Unknown 1 resectable Hilar CC 4 mm deep
complete
response
PDT is feasible as
neoadjuvant
therapy
3 Gerhards et al.,
200034
retrospective
review
EBRT prevention of
implantation
metastases
post ERCP/
PTC
19 resectable Hilar CC 0% implantation
metastases
versus 20% if no
neoadjuvant tx
reduced risk of
implantation
metastases
4 Wiedmann
et al., 200338
non-randomized
prospective
study
PDT feasibility of
PDT in
neoadjuvant
setting
7 advanced
tumors
Hilar CC 100% R0
resection
low risk therapy
with improved
resectability
5 Witzigmann
et al., 200621
non-randomized
prospective
study
PDT only
comparison
of all
resected
versus all
palliative
8 not described Hilar CC 87.5% R0
resection
R1/R2 resection not
different than
palliative PDT
(7 patients used
also in prev.
study)
6 Nelson et al.,
200833
retrospective
review
5-FU and
EBRT 
brachytherapy
Downstaging 12 10 unresectable Hilar and
distal CC
11/12 had R0
resection
similar survival,
similar
complication
rates, improved
resectability with
neoadjuvant
7 Katayose et al.,
201137
phase I study gemcitabine
and EBRT
recommended
dose
identification
12 resectable all extrahepatic
CCs
RD gemcitabine
600 mg/m2
RD gemcitabine
600 mg/m2
8 Glazer et al.,
201232
retrospective
review
gemcitabine
based, no
further
specification
comparison of
neoadjuvant
versus
surgery
upfront
28 resectable all biliary tract
cancers
surgery delayed by
6.8 months,
median survival
42.3 versus 53.5
months if no
neoadjuvant
do not delay
surgery with
neoadjuvant
therapy if
resectable
A1 Sano et al.,
201131
case report Gemcitabine Downstaging 1 unresectable Hilar CC 18 months post op
no recurrence
potential
therapeutic option
A2 Tada et al.,
201230
case report gemcitabine
and S-1
Downstaging 1 unresectable Hilar CC 29 months post op
no recurrence
potential
therapeutic option
n neo, sample size receiving neoadjuvant therapy, EBRT, external beam radiation therapy, CC, cholangiocarcinoma, PDT, photodynamic therapy.
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gemcitabine when combined with radiation as neoadjuvant
therapy is 600 mg/m2. This study gave the foundation for an
ongoing phase II study, interim results of which were presented at
the 2011 European Multidisciplinary Cancer Congress in Stock-
holm, Sweden in September 2011 as a poster.39 These results sug-
gested safety of phase II so far and continuation of this study. No
further details are available to date.
The other two prospective studies are both phase II non-
randomized trials. In 2003, Wiedmann et al.38 published a single
arm trial in which seven patients with advanced hilar cholangi-
ocarcinoma were treated with neoadjuvant photodynamic
therapy and subsequently underwent a surgical resection. Initial
resectability is not described, the paper only describes ‘advanced
hilar cholangiocarcinoma’ which were Bismuth–Corlette types III
and IV and type II with wide extension into the bile duct. All
patients were subsequently resected with clear margin and
minimal complications. Based on this study it is not possible to
determine what the clinical implication of this result is besides the
suggestion that it is a low-risk therapy that results in complete
tumour destruction into the depth of 4 mm.
The second phase II study21 uses the updated Wiedmann’s38
database of patients. The main objective of this article WAS the
comparison of curative intent surgical and palliative patients in
their outcomes. A subset of eight patients after neoadjuvant
therapy is a part of the surgical arm. Again, the indication was
‘advanced hilar cholangiocarcinoma’ without description of
resectability. This study has not focused on a description of the
neoadjuvant group separately in all outcomes. As a result the
conclusion can only be that in this cohort seven out of eight
patients after neoadjuvant therapy underwent an R0 resection and
that there was a trend towards improved survival with a 5-year
survival of 42 versus 19% in the upfront surgery group. The major
limitation of these two trials21,38 is the possibility that all eight
patients could have undergone an R0 resection without the use of
PDT. There is no evidence that PDT improves resectability or
helps with downstaging. The conclusion should in that case be
only the safety of resection after PDT.
Discussion
Literature extensively describes the pathological response of unre-
sectable hilar cholangiocarcinoma to chemo, radiation and pho-
todynamic therapy in a palliative setting.14–20 It is not well codified
how this translates to a clinical response in terms of subsequent
resectability and outcomes after a resection.
During the systematic review of the current literature, the
authors identified several hundred guidelines, non-systematic
reviews and expert opinions on this topic. The vast majority of
them suggested that there is lack of evidence to support the use of
neoadjuvant therapy. They suggest aggressive upfront surgical
therapy as the only hope for a cure or long term survival. They also
suggest accepting the significant risk of performing R1 or R2
resections which have outcomes comparable to palliative therapy
only. It is both surprising and concerning that these recommen-
dations are made based on maximum eight studies and two case
reports that actually do not present any evidence to suggest
against such strategy at all. It is true, that their poor quality, low
sample sizes and bias associated with case studies, retrospective
and non-randomized prospective studies does not offer sufficient
evidence to support neoadjuvant therapy and re-assessment for a
resection. On the other hand, the results of these studies are
encouraging enough to suggest development of properly designed
phase II studies in order to offer answers to the research question.
Most common limitations of the included studies were use of
multiple neoadjuvant treatment protocols within studies, a lack of
a description of initial resectability, a lack of a description of the
proportion of patients with a pre-treatment biopsy proving
malignancy as well as insufficient details regarding intra-operative
handling of the vessels. Another major limitation of identified
studies is a combination of patient populations with different
diagnoses that have different therapeutic options and different
outcomes (intrahepatic, hilar, extrahepatic cholangiocarcinoma
and even inclusion of other types of biliary tract cancers in the
same analysis).
As a result of this systematic review, the authors conclude that
there is currently no evidence to suggest improved outcomes with
neoadjuvant therapy compared with upfront resection in resect-
able patients. There is evidence to suggest improved R0 resecta-
bility after neoadjuvant therapy and improved survival when
neoadjuvant therapy is followed by a surgical resection in prima-
rily unresectable patients. Both of these suggestions come from
level 4 evidence.
Given the relatively low incidence of these tumours, well-
designed phase II studies should be carried out to study this
question. In order to provide guidance to researchers in terms of
neoadjuvant strategies, the authors summarized the neoadjuvant
therapies from included studies in Table 2 (studies using PDT are
not included in the table as PDT has a limited role in downstag-
ing). From the table it becomes obvious that there is no standard
protocol or timing of subsequent surgery that should be further
studied. An alternative to the described options30–34,36,37 or current
therapies with well-described response rates in the palliative set-
ting16 can be the Mayo protocol of neoadjuvant therapy used prior
to liver transplantation.23
Future studies should meticulously describe initial diagnosing
process, the reason for unresectability and selection criteria for
neoadjuvant therapy, the therapy itself including details of surgi-
cal procedures such as vascular resections. Outcome descriptions
should include rates of R0 resections, complete and partial
response rates, post-operative morbidity and survival for each
group of patients separately. This would eliminate the majority of
limitations of previous studies. Again, given the relatively low
incidence it is very likely that systematic reviews and meta-
analyses will play a major role in answering more specific ques-
tions in the future. Therefore standardization is imperative to
enable such research.
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